Early safety study of berubicin in people whose brain tumors came back
Original title: Phase I trial and pharmacokinetic study of berubicin (RTA 744) in patients with recurrent or refractory high-grade gliomas.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a first test in people to find a safe dose, not proof that the drug works.
The short version
A first study in people tested a new drug for brain tumors that returned, mainly to find a safe dose.
What was studied. Thirty-five people with brain cancer that came back or stopped responding to treatment took part. Some had glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. They got a drug called berubicin through a vein for 3 days in a row, every 21 days.
What they found. The highest daily dose people could take safely was 7.5 mg/m2. Side effects outside the blood counts were small, and no heart damage was seen. Out of 35 people, 1 had a complete response that lasted, 1 had a partial response, and 9 had disease that stayed stable.
What this means, and what it doesn't
What it could mean: Berubicin was designed to cross into the brain. In this early study, doctors were able to give it with side effects that stayed low. A small number of people saw their tumor shrink or stop growing.
What it doesn't mean: This does not mean berubicin works. It was a first stage study in people. The main goal was to find a safe dose, not to show the drug helps people live longer. Most people in the study did not respond. The drug is not approved, and this is not a cure. It is still a long way from being care your doctor can offer.
Source: PubMed, July 31, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.